{"entity":{"id":"nct04969315","kind":"trial","name":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma","aka":[],"tldr":"A phase 1/2 trial of TT-10 in renal cell carcinoma, prostate cancer, non-small-cell lung cancer and mesothelioma, run by Portage Biotech, now recruiting.","summary":"TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma is a phase 1/2 interventional study registered as NCT04969315 by Portage Biotech, with 35 participants planned, started 2023-06-23 and due to reach its primary completion in 2028-12-01. Interventions recorded: TT-10 and TT-4.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04969315","url":"https://clinicaltrials.gov/study/NCT04969315"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc","prostate","nsclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04969315","phase":"1/2","setting":"A Phase 1/1b, Open-Label, First-in-Human Multicenter Study to Assess the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of Oral TT-10 (an Adenosine 2A Receptor Antagonist), and TT-4 Diacid (an Adenosine 2B Receptor Antagonist), as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors","sponsor":"Portage Biotech","enrolled":35,"outcomes":[]},"route":"/trials/nct04969315/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}]}}